Peripheral T-cell subsets in radiofrequency ablation for tumors from different origins

Asian J Surg. 2024 Mar;47(3):1378-1382. doi: 10.1016/j.asjsur.2023.12.089. Epub 2023 Dec 29.

Abstract

Backgrounds: Radiofrequency ablation (RFA) is known to destroy tumoral tissue and activate immune cells. This study aimed to investigate the impact of RFA on peripheral T-cell responses and its relationship with tumor origin and hepatitis status.

Methods: A retrospective analysis was conducted on 62 patients with various types of tumors, including hepatocellular carcinoma, colorectal cancer, lung cancer, breast cancer, and others, who underwent RFA treatment between June 2017 and December 2018. Blood samples were collected before and one day after RFA treatment. The peripheral T-cell subsets were measured by flow cytometry, and their changes were analyzed.

Results: The study found a decrease in the CD4+CD8-and CD4-CD8+ T-cell subsets after RFA, but no significant changes were observed in the populations of CD4+CD8+ and the CD4+CD8-/CD4-CD8+ ratio. Furthermore, no significant differences were observed in peripheral T-cell subsets concerning tumor type or hepatitis status.

Conclusions: The study suggests that RFA treatment may have a short-term impact on peripheral T-cell responses, characterized by a decrease in certain T-cell subsets. However, these changes do not seem to be related to the tumor type or hepatitis status of the patients.

Keywords: Cancer; Hepatitis; Lymphocyte; Radiofrequency ablation; T-cell.

MeSH terms

  • Carcinoma, Hepatocellular* / surgery
  • Catheter Ablation*
  • Hepatitis* / surgery
  • Humans
  • Liver Neoplasms* / surgery
  • Radiofrequency Ablation*
  • Retrospective Studies
  • T-Lymphocyte Subsets